BR112020004429A2 - uso de dantroleno ou um sal farmaceuticamente aceitável do mesmo para obtenção de uma composição farmacêutica - Google Patents
uso de dantroleno ou um sal farmaceuticamente aceitável do mesmo para obtenção de uma composição farmacêutica Download PDFInfo
- Publication number
- BR112020004429A2 BR112020004429A2 BR112020004429-6A BR112020004429A BR112020004429A2 BR 112020004429 A2 BR112020004429 A2 BR 112020004429A2 BR 112020004429 A BR112020004429 A BR 112020004429A BR 112020004429 A2 BR112020004429 A2 BR 112020004429A2
- Authority
- BR
- Brazil
- Prior art keywords
- dantrolene
- pharmaceutical composition
- individual
- use according
- neurotoxic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762554049P | 2017-09-05 | 2017-09-05 | |
| US62/554,049 | 2017-09-05 | ||
| US201862674406P | 2018-05-21 | 2018-05-21 | |
| US62/674,406 | 2018-05-21 | ||
| PCT/US2018/049515 WO2019050923A1 (en) | 2017-09-05 | 2018-09-05 | METHODS OF USING DANTROLENE TO TREAT EXPOSURE TO A NEUROTOXIC AGENT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020004429A2 true BR112020004429A2 (pt) | 2020-10-20 |
Family
ID=63708449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020004429-6A BR112020004429A2 (pt) | 2017-09-05 | 2018-09-05 | uso de dantroleno ou um sal farmaceuticamente aceitável do mesmo para obtenção de uma composição farmacêutica |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20200383954A1 (https=) |
| EP (1) | EP3678659B1 (https=) |
| JP (2) | JP2020532555A (https=) |
| KR (1) | KR20200047655A (https=) |
| CN (1) | CN111093652A (https=) |
| AU (1) | AU2018328131B2 (https=) |
| BR (1) | BR112020004429A2 (https=) |
| CA (1) | CA3074732A1 (https=) |
| IL (1) | IL272847B1 (https=) |
| MA (1) | MA50080A (https=) |
| MX (2) | MX2020002485A (https=) |
| SG (1) | SG11202001749SA (https=) |
| UA (1) | UA126688C2 (https=) |
| WO (1) | WO2019050923A1 (https=) |
| ZA (1) | ZA202001258B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022538608A (ja) * | 2019-06-28 | 2022-09-05 | ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア | アルツハイマー病の治療のための鼻腔内ダントロレン投与 |
| WO2023081873A1 (en) * | 2021-11-05 | 2023-05-11 | Quorum Innovations, Llc | Materials and methods for preventing or reducing toxicity to organophosphates and other toxic materials |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7758890B2 (en) * | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| EP1603513B1 (en) * | 2003-03-04 | 2020-12-30 | Lyotropic Therapeutics, Inc. | Dantrolene compositions |
| WO2013040501A1 (en) * | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
| DK2925327T3 (da) * | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
-
2018
- 2018-09-05 UA UAA202002205A patent/UA126688C2/uk unknown
- 2018-09-05 BR BR112020004429-6A patent/BR112020004429A2/pt unknown
- 2018-09-05 JP JP2020512813A patent/JP2020532555A/ja active Pending
- 2018-09-05 MX MX2020002485A patent/MX2020002485A/es unknown
- 2018-09-05 US US16/644,281 patent/US20200383954A1/en not_active Abandoned
- 2018-09-05 WO PCT/US2018/049515 patent/WO2019050923A1/en not_active Ceased
- 2018-09-05 MA MA050080A patent/MA50080A/fr unknown
- 2018-09-05 KR KR1020207009450A patent/KR20200047655A/ko not_active Ceased
- 2018-09-05 EP EP18779490.4A patent/EP3678659B1/en active Active
- 2018-09-05 CA CA3074732A patent/CA3074732A1/en active Pending
- 2018-09-05 CN CN201880057290.XA patent/CN111093652A/zh active Pending
- 2018-09-05 AU AU2018328131A patent/AU2018328131B2/en active Active
- 2018-09-05 SG SG11202001749SA patent/SG11202001749SA/en unknown
-
2020
- 2020-02-23 IL IL272847A patent/IL272847B1/en unknown
- 2020-02-27 ZA ZA2020/01258A patent/ZA202001258B/en unknown
- 2020-03-04 MX MX2023012415A patent/MX2023012415A/es unknown
-
2021
- 2021-12-02 US US17/540,878 patent/US20220087980A1/en active Pending
-
2023
- 2023-01-27 JP JP2023010846A patent/JP2023055802A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023055802A (ja) | 2023-04-18 |
| EP3678659C0 (en) | 2025-12-17 |
| MX2020002485A (es) | 2020-07-20 |
| SG11202001749SA (en) | 2020-03-30 |
| RU2020112318A (ru) | 2021-10-06 |
| NZ762056A (en) | 2025-10-31 |
| JP2020532555A (ja) | 2020-11-12 |
| AU2018328131B2 (en) | 2024-04-18 |
| US20200383954A1 (en) | 2020-12-10 |
| EP3678659A1 (en) | 2020-07-15 |
| UA126688C2 (uk) | 2023-01-11 |
| MA50080A (fr) | 2020-07-15 |
| IL272847B1 (en) | 2026-03-01 |
| MX2023012415A (es) | 2023-11-01 |
| CA3074732A1 (en) | 2019-03-14 |
| US20220087980A1 (en) | 2022-03-24 |
| AU2018328131A1 (en) | 2020-03-12 |
| ZA202001258B (en) | 2023-10-25 |
| RU2020112318A3 (https=) | 2021-10-26 |
| EP3678659B1 (en) | 2025-12-17 |
| CN111093652A (zh) | 2020-05-01 |
| IL272847A (en) | 2020-04-30 |
| WO2019050923A1 (en) | 2019-03-14 |
| KR20200047655A (ko) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vargesson | Thalidomide‐induced teratogenesis: History and mechanisms | |
| Eichelman | Toward a rational pharmacotherapy for aggressive and violent behavior | |
| ES2335067T3 (es) | Uso de duloxetina en el tratamiento de la fibromialgia. | |
| Clarke et al. | Use of intravenous lipid emulsion to treat ivermectin toxicosis in a Border Collie | |
| PT2275086E (pt) | Formulação de volume reduzido de acetato de glatirâmero e métodos de administração | |
| WO2000003713A1 (en) | Treatment for schizophrenia and other dopamine system dysfunctions | |
| JP6137833B2 (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| Marks et al. | 5, 7-DHT-induced muricide: inhibition as a result of preoperative exposure of rats to mice | |
| Schultz et al. | The anticholinergic and antiglutamatergic drug caramiphen reduces seizure duration in soman-exposed rats: synergism with the benzodiazepine diazepam | |
| Wetherell et al. | Development of next generation medical countermeasures to nerve agent poisoning | |
| JP2023055802A (ja) | ダントロレンを使用して神経薬暴露を治療する方法 | |
| Kirmayer et al. | Malignant hyperthermia in a dog: case report and review of the syndrome | |
| Palaniappen | Current concepts in the management of organophosphorus compound poisoning | |
| Fieve et al. | Rubidium chloride ingestion by volunteer subjects: initial experience | |
| Thomas et al. | In vivo evaluation of a1 adenosine agonists as novel anticonvulsant medical countermeasures to nerve agent intoxication in a rat soman seizure model | |
| US20180221380A1 (en) | Use of 5H-Dibenz/b,f/Azepine-5-Carboxamide Derivatives for Treating Fibromyalgia | |
| Myhrer et al. | Supralethal poisoning by any of the classical nerve agents is effectively counteracted by procyclidine regimens in rats | |
| Guarnieri et al. | Subcutaneous Implants of a Cholesterol‐Triglyceride‐Buprenorphine Suspension in Rats | |
| RU2817851C2 (ru) | Способы применения дантролена для лечения воздействия нервно-паралитического вещества | |
| DeTolla et al. | Subcutaneous implants of buprenorphine‐cholesterol‐triglyceride powder in mice | |
| Nekoukar et al. | The key role of magnesium sulfate in the management of organophosphorus pesticide poisoning: a scoping literature review | |
| Kabeš et al. | Biological correlates of piracetam clinical effects in psychotic patients | |
| RU2415668C2 (ru) | Способ лечения и профилактики отравлений фосфорорганическими инсектицидами (фои) | |
| Isseroff | Facilitation of delayed spontaneous alternation behavior in adult rats following early hydroxyzine treatment: Differential sensitivity in late infancy | |
| Thomas et al. | Pharmacological Evaluation of Candidate Adenosine Agonists as Novel Anticonvulsant Medical Countermeasures to Soman Nerve Agent Intoxication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |